Literature DB >> 5414540

A comparison of nitrogen mustard and vinblastine sulfate in the treatment of patients with Hodgkin's disease.

R E Alison, D M Whitelaw.   

Abstract

In a crossover study the effectiveness of intermittent maintenance doses of nitrogen mustard was compared to that of vinblastine sulfate in the treatment of 61 patients with advanced Hodgkin's disease. Forty-five of the patients had had previous radiation therapy. Nine of 29 patients who received nitrogen mustard as the first drug had a complete response and five had a partial response. The comparative results in 32 patients receiving vinblastine sulfate first were nine complete responses and 13 partial responses. The median duration of the complete responses to each drug was 43 weeks. The partial responses were of shorter duration. When the second drug was given in adequate doses, almost as many patients responded with a similar median duration of response.It is concluded that nitrogen mustard and vinblastine sulfate are equally effective single agents in the treatment of patients with advanced Hodgkin's disease and that patient preference would favour vinblastine sulfate because of its negligible side effects.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5414540      PMCID: PMC1946387     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  3 in total

1.  Clinical experience with vinblastine sulfate.

Authors:  O H WARWICK; R E ALISON; J M DARTE
Journal:  Can Med Assoc J       Date:  1961-09-02       Impact factor: 8.262

2.  Vincaleukoblastine in the treatment of malignant disease.

Authors:  D M WHITELAW; J M TEASDALE
Journal:  Can Med Assoc J       Date:  1961-09-02       Impact factor: 8.262

3.  Vinblastine vs. nitrogen mustard therapy of Hodgkin's disease.

Authors:  E Z Ezdinli; L Stutzman
Journal:  Cancer       Date:  1968-08       Impact factor: 6.860

  3 in total
  1 in total

Review 1.  Antineoplastic and immunosuppressive drugs. II. Therapeutic uses.

Authors:  M D Cridland
Journal:  Drugs       Date:  1972       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.